v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Jul. 31, 2018
Jul. 31, 2017
Jul. 31, 2018
Jul. 31, 2017
Revenue $ 362,500 $ 362,500 $ 1,112,500 $ 362,500
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses related to patent assertion 241,157 141,127 767,180 143,473
Amortization of patents 81,324 81,325 243,972 243,973
Research and development expenses (including non-cash share-based compensation expenses of $2,472,489, $64,705, $2,668,315 and $213,333, respectively) 2,942,071 362,968 4,380,137 1,245,722
General and administrative expenses (including non-cash share-based compensation expenses of $2,098,793, $416,411, $2,516,652 and $719,440, respectively) 2,703,752 1,508,005 4,602,555 3,067,235
Total operating costs and expenses 5,968,304 2,093,425 9,993,844 4,700,403
Loss from operations (5,605,804) (1,730,925) (8,881,344) (4,337,903)
Gain on extinguishment of patent acquisition obligation (Note 6) 1,547,608
Interest expense (71,667) (442,693)
Interest income 12,228 8,192 29,780 9,817
Loss before income taxes (5,593,576) (1,794,400) (8,851,564) (3,223,171)
Provision for income taxes
Net loss (5,593,576) (1,794,400) (8,851,564) (3,223,171)
Less: Net loss attributable to noncontrolling interest (116,650) (158,032)
Net loss attributable to common shareholders before deemed dividend (5,476,926) (1,794,400) (8,693,532) (3,223,171)
Deemed dividend to preferred shareholder (Note 7) (2,008,775)
Net loss attributable to common shareholders $ (5,476,926) $ (1,794,400) $ (8,693,532) $ (5,231,946)
Net loss per common share attributable to common shareholders:        
Basic and diluted (in Dollars per share) $ (0.30) $ (0.12) $ (0.50) $ (0.47)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 18,431,025 14,561,754 17,257,546 11,030,992

Source